Menu
Back to Journals » OncoTargets and Therapy » Volume 12
Original Research
The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,363 | Dovepress* | 6,848+ | 1,028 | 7,876 | |
| PubMed Central* | 1,515 | 334 | 1,849 | ||
| Totals | 8,363 | 1,362 | 9,725 | ||
| *Since 8 July 2019 | |||||
View citations on PubMed Central and Google Scholar